Liver study checks how cenerimod behaves in the body

NCT ID NCT04819464

Completed Knowledge-focused Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how a single 0.5 mg dose of the drug cenerimod is processed in 24 people — some with mild or moderate liver impairment and some healthy. The goal was to see if liver problems change drug levels or safety. Participants were monitored for side effects and drug concentration in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cenerimod (a single 0.5 mg oral dose)
What this could lead to: If successful, this study could help doctors understand how to dose cenerimod safely for patients with liver problems.
What could go wrong: This is an early Phase 1 study with only 24 people, so results may not apply to everyone. It only tests a single dose, not long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY HEPATIC IMPAIRMENT

Contacts and locations

Show contact details

Locations

BlueClinical Phase 1 Hospital de Prelado

Porto, 4250-449, Portugal
CRU Hungary

Kistarcsa, H2143, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.